Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer
Status:
Completed
Trial end date:
2021-08-26
Target enrollment:
Participant gender:
Summary
This is a non-randomized, single arm, multi-center, phase II study of pembrolizumab in
combination with doxorubicin in subjects with recurrent/metastatic endometrial cancer.